Czech/SlovakiaCzech RepublicSlovakia

Zentiva Plans Initial Public Offering

07.06.2004

Prague - The Czech generics pharmaceutical company Zentiva a.s. intends to seek a listing on the Prague and London Stock Exchanges through a global offering of shares and GDRs (Global Depositary Receipts). The shares are being offered in the Czech Republic. In the United States and elsewhere outside the Czech Republic shares and GDRs are only being offered to certain institutional investors. Merrill Lynch International has been appointed global co-ordinator, sole book runner and lead manager to the offer.
“We are delighted that Zentiva is to become a public company by being the first company to undertake a significant IPO on the Prague Stock Exchange. The offering will facilitate our strategy of expansion into
other key Central and Eastern European markets,” said Jiri Michal, chairman of the board and CEO of Zentiva. The company develops, manufactures and markets branded generic pharmaceutical products. It is one of the largest pharmaceutical companies in the region and on a combined basis the largest generic pharmaceutical supplier in its four core markets of the Czech Republic, Slovakia, Poland and Russia.
In August 2003, Zentiva increased its critical mass in Slovakia, Poland and Russia with the acquisition of Slovakia's largest generic player Slovakofarma. The former Leciva and Slovakofarma now market their pharmaceutical products under the name Zentiva in all markets. Based on IMS data Zentiva's market share by value for generic pharmaceutical products amounts to 51% in the Czech Republic and to 61% in Slovakia.

Czech/SlovakiaCzech RepublicSlovakia

24.09.2007

Prague/Norwood – The international clinical trial company Medpace Inc. (Norwood, USA) has acquired the Czech contract research organisation Monax s.r.o. (Prague) for an undisclosed sum. With the acquisition, which the firm...

Czech/SlovakiaCzech RepublicSlovakia

11.07.2007

Prague/Foster City – An oligonucleotide analogon, originally developed at the Institute of Organic Chemistry and Biochemistry (IOCB) at the Czech Academy of Sciences in Prague, has entered clinical testing as treatment for...

Czech/SlovakiaCzech RepublicSlovakia

17.05.2007

Prague/Leuven – The Czech Republic is lagging behind in applying the ten year-old European convention on Human rights and biomedicine, according to a new report from EuroGentest, an EU-funded Network of Excellence, which assesses...

Czech/SlovakiaCzech RepublicSlovakia

21.11.2006

BIOTEC 2006, the first international biotechnology conference and exhibition in Eastern Europe, held at the end of October, staged the official inauguration ceremony of the International Clinical Research Center (ICRC). The...

Czech/SlovakiaCzech RepublicSlovakia

16.09.2006

In order to keep track of developments and to promote network-creation, for both domestic-domestic and domestic-foreign cooperations the South Moravian Innovation Centre, Brno, has conducted the Czech Republic’s first...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Bratislava – In late-April, the Slovak government authorized field trials with genetically modified MON 810 maize at three undisclosed locations. The total area of the field trials is approximately 30 hectares. Although Slovakia...

Czech/SlovakiaCzech RepublicSlovakia

21.07.2006

Pruhonice – Biomass production is a promising alternative for the Czech Republic’s agricultural sector. Biomass could cover the annual domestic bio-energy demand of 250 PJ (predicted for 2030), and could be exported as bio-fuels...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Prague - The French pharma giant Sanofi-Aventis S.A. strengthened its generics business in Central and Eastern Europe (CEE) with a participation in the Czech generics producer Zentiva a.s. According to Sanofi-Aventis, the company...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2006

Brno - The International Clinical Research Center (ICRC) in Brno, will collaborate with the renowned Mayo Clinic in Rochester, MN, to establish a clinical and research education center that meets the challenges of 21st-century...

Czech/SlovakiaCzech RepublicSlovakia

17.03.2006

Humpolec - A product derived from genetically modified potatos with altered starch composition poses no threat to human health, according to a European Food Safety Authority (EFSA) panel ruling.BASF Plant Science's GM potato,...

Displaying results 31 to 40 out of 70

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/3/article/zentiva-plans-initial-public-offering.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 18.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper